CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 43 enrolled
Drug / intervention
Spectra Optia® Apheresis Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02302365
NCT02302365N/ACompleted
CompareCT.gov

Multicenter, Retrospective Data Collection of Routine Clinical Use With the Spectra Optia® Apheresis System for White Blood Cell Depletion

Terumo BCT·observational·Posted Nov 27, 2014·Updated Jul 3, 2018

In Brief

An observational study evaluating Spectra Optia® Apheresis System for Leukocytosis. Completed, enrolled 43 participants across 3 sites in 3 countries.

Detailed Summary

This study is a multicenter, retrospective data collection of routine clinical use with the Spectra Optia® apheresis system for white blood cell depletion.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLeukocytosis
CountriesBelgium, Germany, Hungary
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 27, 2014
Enrollment StartApr 1, 2014
Primary CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 11.6 years ago

Interventions

Spectra Optia® Apheresis Systemdevice

White Blood Cell Depletion